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Abstract
Background: It is now evident that HAART-associated immunological improvement often leads to a variety of new clinical
manifestations, collectively termed immune reconstitution inflammatory syndrome, or IRIS. This phenomenon has already
been described in cases of HIV coinfection with Mycobacterium leprae, most of them belonging to the tuberculoid spectrum
of leprosy disease, as observed in leprosy reversal reaction (RR). However, the events related to the pathogenesis of this
association need to be clarified. This study investigated the immunological profile of HIV/leprosy patients, with special
attention to the cellular activation status, to better understand the mechanisms related to IRIS/RR immunopathogenesis,
identifying any potential biomarkers for IRIS/RR intercurrence.
Methods/Principal Findings: Eighty-five individuals were assessed in this study: HIV/leprosy and HIV-monoinfected
patients, grouped according to HIV-viral load levels, leprosy patients without HIV coinfection, and healthy controls.
Phenotypes were evaluated by flow cytometry for T cell subsets and immune differentiation/activation markers. As
expected, absolute counts of the CD4+ and CD8+ T cells from the HIV-infected individuals changed in relation to those of
the leprosy patients and controls. However, there were no significant differences among the groups, whether in the
expression of cellular differentiation phenotypes or cellular activation, as reflected by the expression of CD38 and HLA-DR.
Six HIV/leprosy patients identified as IRIS/RR were analyzed during IRIS/RR episodes and after prednisone treatment. These
patients presented high cellular activation levels regarding the expression of CD38 in CD8+ cells T during IRIS/RR (median:
77,15%), dropping significantly (p,0,05) during post-IRIS/RR moments (median: 29,7%). Furthermore, an increase of cellular
activation seems to occur prior to IRIS/RR.
Conclusion/Significance: These data suggest CD38 expression in CD8+ T cells interesting tool identifying HIV/leprosy
individuals at risk for IRIS/RR. So, a comparative investigation to leprosy patients at RR should be conducted.
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Introduction
The introduction of highly active antiretroviral therapy
(HAART) for HIV infection in the mid-1990s is associated with
clinical benefits, including the resolution of opportunistic infections
and malignancies and the decline in hospitalizations and mortality
rates [1]. These benefits are, in part, associated with the
suppression of HIV viremia and the improvement of the immune
function, as indicated by increases in total CD4+ T cell counts [2].
However, it is now also evident that the HAART-associated
increase in immunity often leads to a variety of new clinical
manifestations as a result of the dysregulation of the immune
system or an inflammatory response to both intact subclinical
pathogens and residual antigens [3]–[5]. These manifestations
have been collectively termed immune reconstitution inflamma-
tory syndrome (IRIS) because the phenomenon occurs during
HAART-induced immune recovery and involves a host inflam-
matory response [6]. An increasing number of conditions are
reported as IRIS events, and these most frequently occur in
conjunction with mycobacterial (tuberculosis or Mycobacterium
avium complex infection) and cryptococcal diseases [7]. Prior to
the HAART era, there was ample appreciation that improvements
in the immune function could result in pathological inflammation.
These so-called paradoxical reactions were well described among
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28735non-HIV-infected patients treated for Mycobacterium tuberculosis
infection [8]. Clinical worsening in these patients following the
initiation of anti-M. tuberculosis therapy had been attributed to a
reversal of the immunosuppression induced by this infection.
Despite numerous descriptions of IRIS conditions, its patho-
genesis remains largely unknown. It is now accepted, however,
that it involves a combination of immune restoration activities
following HAART, an underlying antigenic burden, and host
genetic susceptibility [7].
The presence of an antigenic stimulus for the development of the
syndrome appears to be necessary and may derive from an
infectious or noninfectious agent. The source of this antigenic
stimulus could be intact, ‘‘clinically silent’’ organisms or dead or
dying organisms and their residual antigens [4], [5]. Although
uncommon, our group and others have previously described the
IRIS phenomenon in cases of HIV coinfection with Mycobacterium
leprae [9]–[14]. The majority of these reported cases belong to the
tuberculoid spectrum of leprosy, implying that a good host immune
response is involved in this pathological condition. The coexisting
type I leprosy reaction in these individuals further supports the idea
that the recovery of the immunological system causes this
paradoxical response. Similarly to M. tuberculosis, leprosy reaction
most often occurs during multidrug chemotherapy in both
paucibacillary and multibacillary patients [15]. Paucibacillary cases
develop a type 1 or leprosy reversal reaction (RR) while a type 2
reaction develops in multibacillary patients. In RR, the level of cell-
mediated immunity against M. leprae is suddenly elevated, resulting
in an inflammatory response in the skin and nerves affected by the
disease. Inflammatory reactions during treatment are, therefore,
routine in M. Leprae-infected patients.
The pathogenic mechanism receiving the most attention
involves the theory that IRIS is precipitated by the extent of
immune restoration following HAART. Some studies suggest that
differences in baseline CD4+ cell numbers at the beginning of
HAART are responsible [16], [17]. Alternatively, immunological
mechanisms may involve qualitative changes in lymphocyte
function or phenotypic expression, e.g., an increase in memory
CD4+ cells, which are primed to recognize previous antigenic
stimuli [18]. Therefore it can be deduced that other immunolog-
ical factors may be involved in the pathogenesis of IRIS. Chronic
immune activation is a characteristic of HIV disease progression,
which is strongly correlated to HIV RNA levels that decrease as a
result of HAART-induced virological suppression [19]–[21]. In
fact, immune activation has been considered an important cause of
HIV pathogenesis [22], [23]. Differential expression of cellular
activation markers during IRIS/leprosy reversal reaction (IRIS/
RR) episodes should reflect the risk of developing this paradoxical
disease.
This study was designed to evaluate the immunological profile
of HIV/leprosy patients, paying particular attention to cellular
activation states, to better understand the mechanisms leading to
IRIS/RR immunopathogenesis. We also aimed to identify any
potential parameters such as immunophenotypic markers associ-
ated with the occurrence of IRIS/RR to enable the development
of diagnostic criteria and prevention strategies. A clear under-
standing of IRIS pathogenesis is required to investigate its cause,
recognize which individuals are at risk, and develop effective
treatment strategies.
Methods
Ethics Statement
Protocol was approved by the Oswaldo Cruz Foundation Ethics
Committee, which is affiliated to the Brazilian National Ethics
Council, under protocol no. 440/08. Written informed consent
was provided by each individual participant before sample
collection and study procedures began.
Study Groups
Eighty-five individuals were assessed in this study, 42 of whom
were HIV/leprosy coinfected. Seven leprosy patients (without
HIV coinfection), 20 healthy individuals, and 16 previously-
studied HIV patients [24] (without leprosy coinfection) were
included as controls. In accordance with the Brazilian Ministry of
Healthy Consensus Therapy guidelines, all HIV-infected patients
were under a 3-or-more antirretrovial drug regimen at the time of
enrollment, either with or without protease inhibitors, except for 7
HIV/leprosy coinfected individuals,. The leprosy and HIV/
leprosy patients were followed at the Souza Arau ´jo Out-patient
Unit (Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, RJ, Brazil).
Because our focus was the immunological profile of the patients,
especially their immune activation status [20], [21], which may
alter as a result of HIV replication and viral load levels, the HIV/
leprosy-coinfected individuals were first grouped according to their
HIV viral load levels regardless of HAART status. The patients
were classified as belonging to group 1 when their viral load (VL)
levels were ,80 copies/ml (n=24), as group 2 when their VL
levels were $80,10,000 copies/ml (n=12), and group 3, when
the patients presented VL levels $10,000 copies/ml (n=6).
Similarly, HIV-monoinfected individuals were divided into 2
groups: the undetectable VL group whose VL levels were the limit
of detection (VL,LD), and the detectable VL group (VL$LD)
whose VL values were $80 copies/ml.
In light of their clinical leprosy status, HIV/leprosy patients
were classified by way of Ridley and Jopling criteria in the absence
of any RR symptoms as IRIS/RR at the time of RR, and post-
IRIS/RR at the completion of treatment with glycocorticoid
prednisone 6 months afterward. The 7 leprosy patients were also
evaluated according to Ridley-Jopling criteria.
Viral Load Evaluation
Quantification of the plasma viral load was determined for all
HIV/leprosy coinfected patients at each visit using nucleic acid
sequence-based amplification (NASBA, Organon Teknika, Boxtel,
The Netherlands), which has a lower detection limit of 80 copies/
ml.
Flow cytometry analysis
Lymphocytes were immunolabeled using a combination of
CD4-Cy-chrome, (PE-Cy5, IgG1, clone RPA-T4) and CD8-Cy-
chrome (PE-Cy5, IgG1, clone RPA-T8) antibodies to discriminate
among the T cell populations. CD45RA- fluorescein isothiocya-
nate (FITC, clone HI100, IgG2b) and CD45RO-phycoerythrin
(PE, clone UCHL1, IgG2a) (BD-Biosciences, Franklin Lakes, NJ,
USA) were used to define cellular differentiation status and dual-
color staining with CD8 (FITC, IgG1, clone MCD8) and CD38
(PE, IgG1, clone T16) or CD3 (FITC, IgG2b, clone UCHT1) and
HLA-DR (PE, IgG2a, clone BRA30) (IQ Products, Groningen,
The Netherlands) antibodies to analyze cellular activation. Five
microliters of each antibody were distributed among the sample
tubes, and 50 ml of fresh peripheral blood (in EDTA) was added.
The samples were then mixed gently and incubated for 30 min at
room temperature in the dark. Cell lysis was performed by adding
450 mL of FACS Lysing solution
TM (BD Biosciences). Samples
were then washed twice in PBS solution and fixed with PBS plus
1% paraformaldehyde, prior to acquisition on a FACSCalibur
(BD Biosciences). At least 10.000 events were acquired in a
lymphocyte gate, and phenotypic analysis was carried out using
Immunopathogenesis of HIV/Leprosy Coinfection
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TM software (BD). The percentages of CD38+ and
HLA-DR+ cells were determined for the CD8+ and CD3+ T cell
populations, respectively.
For CD3+/CD4+ and CD3+/CD8+ T cell subpopulations, the
single-platform method was used to determine absolute counts.
Briefly, 20 ml of TriTEST (BD-Biosciences) three-color (CD4-
FITC, CD8-PE, and CD3-PerCP) antibodies and 50 ml of whole
blood were added to bead-containing TruCount tubes (BD
Biosciences). These were incubated for 15 min at room temper-
ature before 450 ml of FACS Lysing solution
TM was added.
Samples were analyzed within 1 hour.
Results
Epidemiological, clinical and T cell immunological
parameters of the groups studied
Forty-two (30 men and 12 women) HIV/leprosy-coinfected
individuals with a median age of 39.5 (range: 21–69 years) were
evaluated at the time of leprosy diagnosis. The diagnosis of leprosy
was determined subsequent to the detection of HIV positivity in 40
of these individuals. Nearly half of these patients were diagnosed
with leprosy prior to undergoing HAART while the other half was
diagnosed as leprosy patients after HAART. In light of the
classification criteria proposed by Talhari et al [25] for HIV/
leprosy coinfected patients, the first half would be defined as
having M. leprae-HIV true coinfection while the second half
would be considered as having HAART-related leprosy.
According to the clinical status of leprosy and the absence of any
RR symptoms by way of the Ridley and Jopling classification
system, 26 of the 42 HIV/leprosy patients (61.9%) presented the
borderline tuberculoid (BT) form, while 3 individuals (7.1%)
presented the undetermined form, corresponding to the pauciba-
cillary patients. With respect to the multibacillary patients, 6
(14.3%) were mid-borderline (BB), 4 (9.4%) presented the
borderline lepromatous form (BL), and 3 (7.1%), the lepromatous
(LL) form. For the multibacillary patients, the initial bacillary
index median was 1.75, ranging from 0.5 to 4.83. Neurological
impairment was absent in 64.3% of the patients at the outset of
treatment. Among the 7 leprosy non-HIV patients, different
clinical profiles were observed, including BT, BB, and LL.
Indeed, 35 of the 42 HIV/leprosy individuals were under
HAART at the time of enrollment, the majority (57.1%) being
administered the 3-drug regimen including zidovudine, lamivu-
dine, and efavirenz, following the Brazilian Ministry of Health
guidelines. The other patients were under other therapeutic
schemes that included protease inhibitors. However, no differences
were observed in the VL levels of patients administered different
HAART regimens.
In order to evaluate T cell immunological parameters, all 85
individuals were primarily evaluated to quantify their CD3+/
CD4+ and CD3+/CD8+ T cell subpopulations. The median
absolute counts are presented in Table 1. The HIV/leprosy-
infected individuals showed a significant reduction in CD4+ T cell
absolute counts (p,0.05) regardless of VL levels (group 1 median:
336 cells/mm
3; group 2 median: 341 cells/mm
3; group 3 median:
285 cells/mm
3) in comparison to the leprosy patients (median:
1079 cells/mm
3) and the healthy controls (median: 813 cells/
mm
3). This CD4+ T cell absolute reduction is a typical
characteristic of HIV infection. No differences in the CD4+ T
cell absolute count distribution profiles were detected among the
HIV/leprosy-coinfected and HIV-monoinfected groups.
For CD8+ T cell absolute counts, lower values (p,0.01) were
observed in group 1 (median: 783 cells/mm
3) and group 2
(median: 734 cells/mm
3) of the HIV/leprosy patients relative to
the VL$LD HIV-monoinfected ones (median: 1410 cells/mm
3).
Furthermore, HIV/leprosy group 1 had higher CD8+ T cell
counts (p,0.05) when compared to those of the leprosy patients
(median: 542 cells/mm
3). As expected, all HIV/leprosy patients
had significantly higher CD8+ T cell absolute counts (p,0.05)
than the healthy individuals (median: 488 cells/mm
3).
Cellular differentiation status was investigated by analyzing the
surface expression of the CD45RA and CD45RO molecules in
both CD4+ and CD8+ subpopulations (Table 1). For CD4+ T
cells, frequency differences among CD45RA+ circulating cells
were observed only when comparing groups 1 and 2 of the HIV/
leprosy patients (medians: 22.4%, versus 37.7%; p,0.05), with
the latter group showing a higher percentage of circulating cells.
On the other hand, the CD45RO+ fraction of CD4+ T cells did
not show any statistical differences among the study groups
(Table 1).
Table 1. Median and interquartile range (IQR) of T cell immunophenotyping percentage values or absolute counts obtained from
HIV/leprosy individuals according to viral load (VL) values and from HIV-monoinfected, leprosy patients and healthy controls.
HIV/Leprosy HIV-monoinfected Leprosy Healthy Controls
Group 1 Group 2 Group 3 VL,LD VL.LD (n=7) (n=20)
(n=24) (n=12) (n=6) (n=10) (n=6)
CD3+/CD4+ 336 (265–525) 341 (260–488) 285 (141–428)* 392 (379–450) 188 (109–300) 1079 (500–1533)*
,{,{ 813 (703–942)*
,{,{
CD3+/CD8+ 785 (462–1032) 734 (481–944) 921 (730–1303) 907 (792–1288) 1410 (1214–1864)*
,{ 542 (303–608)*
,{ 488 (410–573)*
,{,{
CD4+/CD45RA+ 22.4 (16.3–32.9) 37.7 (24.0–42.2)* 22.8 (15.4–33.3) 25.8 (19.0–31.6) 27.7 (20.2–33.0) 21.6 (16.7–27.5) 31.8 (19.8–44.9)
CD4+/CD45RO+ 66.1 (55.1–80.5) 63.1 (53.4–71.6) 53.9 (46.7–63.3) 64.6 (59.6–75.1) 76.6 (70.9–83.2) 71.7 (58.8–75.6) 58.8 (45.6–74.6)
CD8+/CD45RA+ 37.6 (32.5–40.8) 46.2 (40.0–50.5) 27.3 (22.6–41.3) 44.4 (40.1–48.3)* 36.8 (26.7–53.6)
{ 45.7 (3773–49.4) 47.4 (42.5–62.0)*
CD8+/CD45RO+ 51.5 (41.0–64.2) 53.8 (45.5–65.0) 54.6 (44.9–64.7) 54.4 (42.9–62.4) 68.5 (40.5–81.3) 39.4 (31.5–48.1) 46.7 (34.0–54.2)
CD3+/HLA-DR+ 19.3 (13.4–25.2) 16.4 (10.6–19.1) 39.3 (25.5–58.5)*
,{ 13.2(9.9–17.4)
{ 13.8 (9.2–18.5)
{ 5.8 (4.9–19.8)
{ 8.4 (6.5–13.9)*
,{,{
CD8+/CD38+ 28.9 (15.1–37.5) 37.2 (26.0–68.3) 66.7 (60.2–80.4)* 53.3 (47.2–55.8)* 59.3 (57.7–64.6)* 26.1 (23.0–33.4)
{ 8.7(4.2–13.4)*
,{,{
*p,0,05 – Mann-Whitney U test: groups versus Group 1 HIV/leprosy individuals (VL,LD);
{p,0,05 – Mann-Whitney U test: groups versus Group 2 HIV/leprosy individuals (VL$80,10,000 copies/ml);
{p,0,05 – Mann-Whitney U test: groups versus Group 3 HIV/leprosy individuals (VL$10,000 copies/ml);
LD: limit of detection.
doi:10.1371/journal.pone.0028735.t001
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was found to differ among the groups (Table 1). HIV/leprosy group
1 had a lower percentage ofCD45RA+ cellsthan the VL,LDHIV-
monoinfected and healthy individuals (medians: 37.6%, versus
44.4% and 47.4%, respectively; p,0.05). On the other hand, the
group 2 HIV/leprosy individuals had significantly more
CD8+CD45RA+ T cells than the VL$LD HIV-monoinfected
individuals (medians: 46.2%, versus 36.8%; p,0.0001). No
differences were observed in the proportion of circulating
CD45RO+ CD8+ T cells among the various study groups, however.
Activation parameters were also evaluated in this study,
including the total CD3+ T cell numbers, HLA-DR expression,
and, for CD8+ cells, the expression of CD38. Because the
expression of these activation markers, especially CD38, correlates
strongly with HIV replication and viral load levels [19], [20], the
HIV/leprosy-coinfected individuals were also evaluated according
to their different VL levels.
As shown in Table 1 and Figure 1, a high frequency of CD3+ T
cells expressing HLA-DR was observed in group 3 HIV/leprosy-
infected individuals, in contrast to group 1 and group 2 (medians:
39.3%, versus 19.3% and 16.4%, respectively; p,0.05). In
addition, higher levels of HLA-DR expression were also observed
in groups 1 and 2 HIV/leprosy patients compared to the healthy
individuals (median: 5.8%; p,0,05).
Similarly, differences were also observed in the circulation of
CD8+ T cells expressing CD38 (Table 1, Figure 1). A high
percentage of these cells was observed in group 2 HIV/leprosy
patients (median: 66.7%) in contrast to the leprosy group and
healthy controls (medians: 26.1% and 8.7%, respectively; p,0.01).
However, this expression was not significantly higher than that
seen in the VL,LD and VL$LD HIV-monoinfected groups
(median: 53.3% and 59.3%, respectively). When the HIV/leprosy
patients had their HIV viral load controlled, their activation status
was reduced (group 1 median: 30.7%; p,0.05), and this reduction
was significant relative to that of the VL,LD and VL$LD HIV-
monoinfected patients. The activation levels in HIV/leprosy
group 1 were significantly higher than those among the healthy
controls (p,0.0001), but not the leprosy patients.
Analysis of the IRIS/RR phenomenon
During the study, 9 of the 42 (21.4%) HIV/leprosy patients
were identified as IRIS/RR by way of clinical status. Prior to the
development of IRIS/RR symptoms, 7 were classified as BT while
only 2 (patients Hs040 and Hs 045) were defined as BB.
All patients were under HAART during reaction although the
time that lapsed between HAART submission and the onset of
IRIS/RR varied from 3 months of treatment to 3 years post-
treatment. Of interest, we were also able to quantify the CD4+ T
cells and VL levels of 6 of the 9 IRIS/RR patients, previously to
HAART submission. The CD4+ T cell absolute counts were
under 350 cells/mm
3, with a median value of 114 cells/mm
3
(range: 17–318 cells/mm
3). At the same time, high levels of VL
were obtained, ranging from 20,000 to 5,700,000 copies/ml
(median: 148,600 copies/ml). These patients were highly immu-
nocompromised at baseline accompanied by intense viral
replication. However, at the time of IRIS/RR, VL was virtually
undetectable in 7 of the HIV/leprosy patients, except for 2 who
had 320 (Hs012) and 4,880 copies/ml (Hs043). Indeed, as
expected, their immunological status was restored since all 9
patients presented incremented CD4+ T absolute counts (medina:
408 cells/mm
3 (range: 140–767 cells/mm
3).
The other T cell immunological parameters were also evaluated
in these 9 patients and although no clear pattern of expression was
identified in terms of either cellular differentiation or activation
markers in comparison with the HIV/leprosy patients with no RR
signals, the IRIS/RR patients had high cellular activation levels at
the onset of IRIS/RR. We were able to monitor these patients at
different time points, including the post-IRIS/RR resolution
moment, and interesting results were observed.
Six patients were analyzed at the initiation of an IRIS/RR
episode and after the completion of treatment with prednisone.
Regarding the expression of CD38 in CD8+ T cells, 6 individuals
showed high levels of cellular activation (median: 77.15%; CI:
37.66%–96.13%) at the onset of IRIS/RR (Figure 2A). These
values dropped significantly (p,0.05) post-IRIS/RR after 6
months of therapy with prednisone (median: 29.70%; CI:
11.17%–37.94%). Subsequent to prednisone treatment, cellular
activation levels were significantly lower than those seen in the
VL,LD HIV-monoinfected patients (p,0.01), similar to those
detected in the leprosy patients but higher than that observed
among the healthy controls (p,0.05). This reduction in CD38
expression in CD8+ T cells was clearly seen during flow cytometry
analysis as observed by the cellular migration from the upper left
panel to the upper right panel of the dot-plot graphics in Figure 2B.
Figure 1. The percentage of HLA-DR+ in CD3+ T lymphocytes
(upper panel) and the percentage of CD38+ in CD8+ T
lymphocytes (lower panel) in samples from HIV/leprosy patients
from group 1 (VL,LD), group 2 (VL$80,10,000 copies/ml),
and group 3 (VL$10,000 copies/ml); HIV-monoinfected VL,80
copies/ml and VL.80 copies/ml patients; leprosy-infected
individuals; and healthy controls. Bars represent median values.
* p,0.05 – Mann-Whitney U test for each group compared with HIV/
leprosy patients from group 1; { p,0.05 – Mann-Whitney U test for
each group compared with HIV/leprosy patients from group 2;
{ p,0.05 – Mann-Whitney U test for each group compared with HIV/
leprosy patients from group 3. VL: HIV viral load. LD: Limit of detection.
doi:10.1371/journal.pone.0028735.g001
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levels were higher in those HIV/leprosy patients who also had the
highest activation levels during IRIS/RR, specifically individuals
Hs009, Hs033, Hs040, and Hs043 (Fig. 2A), in comparison to the
Hs015 and Hs024 patients, whose activation levels were lower at
both time points.
Moreover, it is noteworthy that patient Hs009, who was also
evaluated almost 4 months prior to the initiation of an IRIS/RR
episode, already expressed CD38 in 59.82% of the circulating CD8+
T cells. Similarly, patient Hs019, analyzed just 5 days before the
development of IRIS/RR symptoms, expressed CD38 in 77.02% of
the CD8+ cells in contrast to the onset of IRIS/RR, when the
percentage was 86.18%. Therefore, it can be assumed that an increase
in these activated cells occurred prior to the IRIS/RR episodes.
Patient Hs012 was evaluated twice within a one-month period
post-IRIS/RR. At the completion of prednisone therapy (post-
IRIS/RR), 25.70% of the T cells were activated CD8+/CD38+
cells. However, one month later, this number had risen to 62.54%.
This patient is still under surveillance; but, to date, no further
IRIS/RR episodes have been detected.
Discussion
Leprosy remains a significant global health problem, and over
40,000 new cases were registered in Brazil in 2009 [26]. Leprosy
and HIV are two chronic infectious diseases with an overlapping
geographic distribution in Brazil. Nonetheless, valuable informa-
tion regarding the impact of these two diseases on T cell
phenotypes in infected individuals remains scarce.
Immunological interactions between leprosy and HIV have
been a topic of great interest over the last two decades or so. While
an increase in the immunosuppressive form of leprosy (LL) was
expected to occur in HIV/leprosy coinfected patients, this was not
confirmed by follow-up studies. In contrast, occurrences of the
tuberculoid form of leprosy predominate among these coinfected
individuals whatever the T lymphocyte count in the blood [27],
[28]. This was also observed at the present study, where 61.9% of
the 42 HIV/leprosy coinfected patients presented the BT form of
leprosy, while only 13 of them were identified as multibacillary
cases. In the same way and also in contrast to the initially expected
for leprosy and HIV coinfection [29], we observed low frequency
of neurological impairment among the HIV/leprosy patients.
The most interesting phenomenon associated with the interac-
tion between HIV and leprosy infection is the higher incidence of
reversal reactions (RR) [28], suggesting that the immune
regulation of each disease is independent. The higher frequency
of RR after initiating HAART has brought on new challenges to
the full understanding of this immunological phenomenon,
previously been thought to be an M. leprae-specific immune
reactivation. In addition, many of the leprosy cases appearing after
Figure 2. The percentage of CD38+ in CD8+ T lymphocytes obtained from HIV/leprosy-coinfected patients during the development
of immune reconstitution inflammatory syndrome/reversal reaction (IRIS/RR) episodes and at the completion of reaction treatment
with prednisone (Post-IRIS/RR) (Panel A). * p,0.05 – Wilcoxon U test. Representative flow cytometry profile presented by one HIV/leprosy
coinfected patient (Hs040), during an IRIS/RR episode (upper dot plot) and post-IRIS/RR (under dot plot) evaluated for the expression of CD38 in CD8+
T lymphocytes (Panel B).
doi:10.1371/journal.pone.0028735.g002
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have been classified as IRIS. We were able to identify 9 cases of
IRIS/RR phenomenon among our HIV/leprosy coinfected
patients. These individuals presented the symptoms of leprosy
reversal reaction, after the onset of antiretroviral therapy and were
considered among the patients having HAART-related leprosy
[25]. Considering the same IRIS criteria previously used by our
group to define IRIS cases [13], 93 out of 9 IRIS/RR patients
(Hs012, Hs024 and Hs043) can be really defined as IRIS cases,
since they developed the symptoms during the first 6 months of
HAART . However, others studies also identified IRIS cases at
periods of longer than 10 months [30]. In this study, we aimed to
characterize some of the key T cell phenotypes involved in the
HIV/leprosy interaction in coinfected vs. non-coinfected patients
and analyze some major features of the IRIS/RR phenomenon.
We first examined CD4+ T cell counts, the classic immunolog-
ical parameter for HIV infection follow-up. All HIV/leprosy-
coinfected individuals showed a reduction in CD4+ cells, as
expected for HIV- positive individuals, although the median values
were similar or higher than those shown in other studies,
regardless of viral load levels and/or HAART status [22], [23],
[31]. An increase in absolute CD4+ T counts was observed in
HIV/leprosy coinfected patients with undetectable VL levels,
reflecting the quantitative immune reconstitution that occurs as a
consequence of viral replication control and antiretroviral therapy.
Moreover, despite the presence of M. leprae, HIV/leprosy
coinfection exhibited the same CD4+ T cell behavior observed
in HIV-infected patients in the absence of detectable VL under
HAART, consistent with previous studies [23], [24], [31].
The lower levels of CD3+CD8+ T cells observed in groups 1
and 2 HIV/leprosy patients could be also attributed to a more
effective control of viremia in these as opposed to the VL.LD
HIV-monoinfected individuals. These data do not agree with the
more severe immunopathology for HIV/leprosy coinfected
individuals, previously suggested by Carvalho et al [31], probably
due our analysis in terms of different viral load levels. On the other
hand, even with a controlled viral load, when the group 1 was
compared with the leprosy patients and healthy controls a higher
percentage of CD8+ T cells was found. This data would suggest
the effect of residual viremia on the immune system, undetectable
by the currently methodology.
It is important to note that peripheral blood CD4+ or CD8+ T
cell counts do not necessarily reflect either the number or function
of these T cells at the actual sites of coinfection, although the
evaluation of skin lymphocytic infiltrate in HIV/leprosy coinfected
patients demonstrated the predominant involvement of CD8+ T
cells at the site of disease, in granuloma formation, being more
frequent than CD4+ T cells [32].
The CD4+ T cells that express the cell-surface isoforms
CD45RA and CD45RO are major targets in HIV infection
[33]. We evaluated the expression of these molecules by CD4+
and CD8+ circulating T cells, in order to define a cellular
differentiation profile, but low differences were observed among
the studied groups and we were not able to identify any defined
profile. So, this was an important limitation of the present study,
since in order to well define the differentiation pathway for T cells,
many others surface molecules should be investigated [34], [35].
So, these differentiation profiles are currently being investigated in
more detail by our team to better understand naı ¨ve cell behavior,
central and effector memory cells, and other intermediary T cell
fractions in HIV/leprosy coinfection scenario.
The evaluation of the activation parameters showed high
frequencies of HLA-DR expression in CD3+ T cells and CD38+
expression in CD8+ T cells in HIV/leprosy-coinfected individuals,
as was previously observed by the present authors in Leishmania/
HIV-coinfected patients [24]. The HLA-DR molecule is capable
of presenting antigenic peptides to the CD4+ T cell receptor
complex and CD38 may function as an adhesion molecule.
During HIV infection, changes in the expression of these markers
are associated with immune dysfunction and disease progression.
In our study, these expression frequencies, especially CD38 on
CD8+ T cells, appeared to be associated with viral load because
group 3 HIV/leprosy individuals showed the highest activation
profile. However, frequent expression of these markers in the
undetectable viral load group was also detected. Previous reports
have shown that low levels of viral production have been known to
persist in patients regardless of their being under long-term,
effective HAART and that this remaining viremia could have an
important impact on the immune system of some patients
undergoing continuous, effective HAART [36]. Other studies
have also suggested that even those patients with HAART-
mediated viral load suppression show a high percentage of
activated T cells and that this immune activation might be
determined by immunological memory cells [37]. Our observation
that T cell activation markers increased in HIV/leprosy cases
despite low or undetectable HIV RNA levels might also be
explained by the fact that immune activation could be determined
by M. leprae in addition to HIV RNA levels. How the two
pathogens act synergistically to drive immune activation remains
to be fully elucidated.
The pathogenesis of IRIS in leprosy has not yet been clearly
defined, but the re-establishment of CD4+ and CD8+ T
lymphocytes after HAART may explain their development.
Previous studies have shown that cellular responses to some
mycobacterial diseases, such as M. avium complex infection, can be
restored after 2 weeks of HAART in HIV1–infected patients [38].
HIV/tuberculosis patients also show inflammatory episodes
characterized as IRIS after the initiation of HAART [39]. The
increase in CD8+ T cell counts after HAART, independent of the
CD4+ T cell count, may be an explanation for some of these
reactions. Previous studies have demonstrated that the CD8+ T
cell count was a risk factor associated with the development of
herpes zoster after initiation of HAART [40]. Other authors have
proposed that the increase in CD8+ T cells after HAART may
result in clinical hepatitis caused by HBV as well as HCV [41,42].
Increases in the expression of activation markers in effector
CD8+ T cell populations may also provide insight into the
immunopathogenesis of IRIS. Effector CD8+ T cells exhibit
specialized functions such as cytotoxicity, antiviral cytokine
production, telomerase activity, and the production of cytokines
such as IL-2, IFN-c, TNF, perforin, and granzymes. Of these,
IFN-c is known to increase in response to mycobacterial antigens
in patients who developed tuberculosis/IRIS [37]. Once these cells
are distributed in the periphery, they take on an immediate
effector function and, thus, may be able to promote a rapid, but
unsustained, response to peripheral antigens.
Interestingly, the CD38 antigen, a cellular activation marker
previously associated with HIV pathogenesis [43], was significant-
ly elevated in the CD8+ T cells of IRIS/RR individuals in our
study but diminished after prednisone therapy. Of the 9 HIV/
leprosy patients identified as experiencing IRIS/RR, 6 had been
found to fit this profile, and 2 were obviously undergoing IRIS at
the time of reaction. The percentage of CD8+/CD38+ T cells
increased prior to the initial onset of IRIS/RR symptoms. These
data open a promising channel of investigation into CD38
expression, which could be a useful biomarker for identifying
coinfected individuals with activated immune systems at risk of
developing IRIS/RR. Obviously, the evaluation of the leprosy
Immunopathogenesis of HIV/Leprosy Coinfection
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to investigate if the CD38 expression on CD8+ T cells will follow
the same profile.
In summary, leprosy and HIV lead to some similar and some
distinct immune alterations. In HIV-monoinfected and HIV/
leprosy coinfected individuals with high viremia, CD4+ T cell
depletion together with pronounced T cell activation may be
involved in a generalized hyporesponsiveness of the immune
system. In coinfected subjects, HIV apparently controls the overall
immunological scenario, especially in patients with low CD4+ T
counts. HIV and leprosy seem to have no additive effects in that
each infection causes specific immune changes, which do not
appear to contribute to the synergistically unfavorable effects of
coinfection.
Our findings regarding IRIS/RR individuals may prove useful
in designing future studies aimed at identifying patients at risk of
developing IRIS/RR. Future prospective pathogen-specific IRIS
immunological studies will likely be required to increase our
understanding of its pathogenesis and to identify potential
biomarkers for the disease.
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